Introduction
============

In the United States, more than two thirds of the population is overweight (body mass index 25-29.9) or obese (body mass index ≥30). This proportion is smaller in Europe, but continues to increase.[@ref1] The World Health Organization estimates that 1.5 billion adults worldwide are overweight and 500 million are obese. Almost three million adults die each year as a result of being overweight or obese. An estimated 44% of the burden for diabetes has been attributed to these weight problems, as well as 23% and 7-41% of the burdens for ischaemic heart disease and specific cancers, respectively.[@ref2]

Weight loss is not easily accomplished or maintained. Meta-analyses of clinical trials on non-pharmacological strategies for weight reduction have reported 1-6 kg losses that have been difficult to maintain.[@ref3] [@ref4] [@ref5] Meta-analyses of sibutramine and orlistat trials report average weight reductions of 3 kg to 5 kg, but some of the included trials had attrition rates of up to 50% that were possibly due to adverse events, suggesting that the interventions could be less effective in clinical practice.[@ref6] [@ref7] [@ref8] Meta-analyses have found that bariatric surgery reduces long term mortality in obese patients,[@ref9] [@ref10] but the safety risks and the costs of this intervention limit the use for large patient populations.

The risk of developing diabetes escalates with the degree of excess body weight, increasing threefold with a body mass index of 25.0 to 29.9, and 20-fold with an index of 35 and higher compared with a healthy index of 18.5-24.9.[@ref11] The difficulties encountered in the management of type 2 diabetes are indicated by the low proportion (\<50%) of patients treated to therapeutic goals.[@ref12] [@ref13] Problems in treatment management might be related to shortcomings with the currently available drugs, including bodyweight increase (thiazolidinediones, sulphonylureas, and insulin), hypoglycaemia (sulphonylureas, repaglinides, and insulin), and gastrointestinal side effects (metformin and alpha glucosidase inhibitors).[@ref14]

Glucagon-like peptide-1 (GLP-1) is a gut hormone that is secreted from the intestine in response to meal ingestion. GLP-1 based therapy was recently introduced as a new treatment for patients with type 2 diabetes mellitus. Treatment with GLP-1 enhances the endogenous secretion of insulin induced by meal ingestion and inhibits glucagon secretion, thereby improving glucose homoeostasis. Notably, it also suppresses food intake and appetite. Trials of patients with type 2 diabetes suggest that agonists of GLP-1 receptor (GLP-1R) have beneficial effects on metabolic regulation and could lead to weight loss. We did a systematic review and meta-analysis to provide an up to date overview of the beneficial and harmful effects of GLP-1R agonists in patients who are overweight or obese.

Methods
=======

The present systematic review was based on a written protocol.[@ref15] The main objective was to assess the effect of GLP-1R agonists versus placebo, no intervention, or other antidiabetic interventions for weight loss in overweight patients with or without type 2 diabetes mellitus. Secondary outcome measures included changes in systolic and diastolic blood pressure, plasma concentrations of liver enzymes (alanine aminotransferase and alkaline phosphatase activity), total cholesterol, and adverse events. For patients with type 2 diabetes, we also assessed markers of glycaemic control: fasting plasma glucose, glycated haemoglobin (percentage of HbA~1c~), and the proportion of patients achieving a target level of HbA~1c~ less than 7%.

Search strategy for identification of trials
--------------------------------------------

Eligible trials were identified by electronic and manual searches. We planned to include trials irrespective of publication status or quality of bias control. For the electronic searches, we reviewed the Cochrane Library, Medline, Embase, and Web of Science. We did not make any restrictions regarding the trials' language or year of publication. The last search update was May 2011.

In the Cochrane Library, we used the search strategy for "liraglutide", "glucagon-like peptide-1", or "exenatide". For the remaining databases, the search terms included "glucagon-like peptide-1", "liraglutide", or "exenatide"; and "Randomised Controlled Trial" or "random". These terms were adjusted to fit the requirements specified in each database. We searched trial registries using the search portal of the WHO International Clinical Trial Registry Platform ([www.who.int/ictrp/search/en/](http://www.who.int/ictrp/search/en/)).

The reference lists of relevant papers were also reviewed manually. We originally planned to obtain unpublished data from included trials through email correspondence with the first authors of included publications and pharmaceutical companies. Since all trials turned out to be industry funded, we retrieved all additional data by correspondence with pharmaceutical companies.

Review methods and selection criteria
-------------------------------------

Eligible trials were listed and the inclusion criteria were assessed independently by all authors. Excluded trials were listed with the reason for exclusion. Three authors (TV, MC, and LLG) extracted data independently. Disagreements were resolved through discussion. Randomised controlled trials were eligible irrespective of their publication status. We included trials of adult patients with or without type 2 diabetes and who had a body mass index of 25 or more. The GLP-1R agonists assessed were exenatide given twice daily, exenatide given once weekly (as a long acting release), and liraglutide given once daily. The control groups were placebo, no intervention, or antidiabetic drugs. If trials included more than one control group, we included data from the most weight neutral intervention (for example, placebo instead of insulin). We also included randomised comparisons between exenatide and liraglutide. To undertake a review that applied to clinical practice, we only included trials with a duration of at least 20 weeks that assessed clinically relevant doses of at least 10 µg/day for exenatide (5 µg twice daily), 2 mg/week for exenatide once weekly, and 1.2 mg/day for liraglutide once daily.

Assessment of risk of bias
--------------------------

Based on previous evidence, we classed the randomisation methods of selected trials as the primary measure of bias control.[@ref16] We assessed randomisation methods by how the allocation sequence was generated (classed as adequate if based on a table of random numbers, computer generated random numbers, or similar) and concealed (classed as adequate if based on central randomisation, identically coded drug containers, serially numbered opaque sealed envelopes, or similar).

We also extracted information on the following:

1.  \(1\) Blinding (whether the trial was described as double blind or single blind, the method of blinding; whether patients, investigators, outcome assessors, or other individuals participating in the trial were blinded; and whether the adequacy of blinding was assessed)

2.  \(2\) Risk of attrition bias (numbers of and reasons for dropouts and withdrawals, and whether all patients were accounted for in the report and analysis of the trial)

3.  \(3\) Whether the primary outcome measure was defined and reported

4.  \(4\) Whether sample size calculations were done

5.  \(5\) Whether the preset sample size was achieved

6.  \(6\) For trials terminated prematurely, whether this termination was based on predefined criteria

Statistical analysis
--------------------

We did data analyses using Stata version 11 (Stata Corp, TX, USA) and Trial Sequential Analysis 2007 (Copenhagen Trial Unit, Copenhagen, Denmark). We used random effects models for the primary analyses because we expected clinical heterogeneity between trials (owing to different criteria for patient inclusion and different intervention regimens). Results of the meta-analyses were expressed as weighted mean differences for continuous outcomes and relative risks for dichotomous outcomes, both with 95% confidence intervals, and with tau^2^ values and P values as markers of intertrial heterogeneity. For dichotomous outcomes, we calculated the number needed to treat if the outcome measure was significant (that is, the confidence interval did not cross 1). For trials assessing more than one dose of GLP-1R agonist, data from the group allocated to receive the highest dose were included in the primary meta-analysis. We repeated the meta-analysis for the lower doses.

We also repeated the meta-analyses using fixed effects models, to test the robustness of the results after attributing less weight to small trials. We reported the results of the fixed effects meta-analyses only if they differed from those of the random effects models. Regression analysis of funnel plot asymmetry allowed us to assess any evidence of publication bias and small study effects (Egger's test). Subgroup analysis examined the intervention effects in trials on different participants (with or without diabetes) and different interventions (that is, exenatide twice daily, exenatide once weekly, or liraglutide once daily).

We did random effects meta-regression to investigate whether body mass index or trial duration could predict the size of the estimated intervention effects. We also used sequential analysis to assess the robustness of the results after adjusting for multiple comparisons (with repeated cumulative meta-analyses). The sequential analysis was done with alpha set to 5%, power to 80%, and a model based heterogeneity correction of 99%. The intervention effects entered in the sequential analysis were selected on the basis of the observed results.

Results
=======

We identified 694 potentially eligible references using the initial searches (fig 1[](#fig1){ref-type="fig"}). After excluding duplicates and clearly irrelevant references, we retrieved 101 relevant references. Of these references, 76 described subgroup analyses of randomised trials, were non-randomised follow-up studies of trials, or did not assess exenatide or liraglutide at the duration or dose specified in our inclusion criteria. The remaining 25 randomised controlled trials fulfilled our inclusion criteria.[@ref17] [@ref18] [@ref19] [@ref20] [@ref21] [@ref22] [@ref23] [@ref24] [@ref25] [@ref26] [@ref27] [@ref28] [@ref29] [@ref30] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35] [@ref36] [@ref37] [@ref38] [@ref39] [@ref40] [@ref41] We received additional data that were not described in the published reports on trial methods and outcome measures from 17 of the included trials.[@ref17] [@ref18] [@ref19] [@ref22] [@ref24] [@ref25] [@ref26] [@ref30] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35] [@ref36] [@ref37] [@ref39] [@ref40]

![**Fig 1** Flow chart for identification and selection of included randomised trials](vilt892349.f1_default){#fig1}

All the included trials were published as full paper articles between January 2004 and May 2011 (table 1[](#tbl1){ref-type="table"}). The trials were multicentred (mean number of clinical sites 68) and multinational. Most trials were done in the US and Europe. The duration of individual trials ranged from 20 to 52 weeks. Three trials included patients without diabetes[@ref17] [@ref18] [@ref19] in the remaining trials, all patients were diagnosed with type 2 diabetes.

The patient characteristics at baseline and the diagnostic criteria for type 2 diabetes were very similar across trials. Mean body mass index ranged from 29 to 41, and mean weight from 82 to 111 kg, for both the GLP-1R agonist groups and the control groups. For patients with type 2 diabetes, the mean concentration of fasting plasma glucose at baseline ranged from 8.0 to 11.7 mmol/L for GLP-1R agonist groups, and from 8.2 to 11.2 mmol/L for control groups. Mean values of HbA~1c~ at baseline ranged from 7.6% to 10.4% for GLP-1R agonists and 7.4% to 10.3% for controls, respectively.

###### 

 Characteristics of included trials

  Trial               Year   Patients (n)   Intervention                                         Duration (weeks)   Main inclusion criteria
  ------------------- ------ -------------- ---------------------------------------------------- ------------------ -------------------------
  Astrup^17^          2009   371            Liraglutide; orlistate; placebo                      24                 Obesity
  Elkind-Hirsch^18^   2008   60             Exenatide; metformin; exenatide and metformin        24                 Obesity
  Rosenstock^19^      2010   163            Exenatide; placebo                                   24                 Obesity
  Apovian^20^         2010   194            Exenatide; placebo                                   24                 Type 2 diabetes
  Bergenstal^21^      2009   372            Exenatide; insulin                                   24                 Type 2 diabetes
  Bergenstal^22^      2010   491            Exenatide; sitagliptin; pioglitazone                 26                 Type 2 diabetes
  Blevins^23^         2011   252            Exenatide once weekly; exenatide twice daily         24                 Type 2 diabetes
  Bunck^24^           2009   69             Exenatide; insulin glargine                          52                 Type 2 diabetes
  Buse^25^            2004   377            Exenatide; placebo                                   30                 Type 2 diabetes
  Buse^26^            2009   464            Liraglutide; exenatide                               26                 Type 2 diabetes
  Davis^27^           2007   49             Exenatide; insulin                                   20                 Type 2 diabetes
  DeFronzo^28^        2010   137            Exenatide; rosiglitazone                             20                 Type 2 diabetes
  Derosa^29^          2010   128            Exenatide; glibenclamide                             52                 Type 2 diabetes
  Diamant^30^         2010   456            Exenatide; insulin glargine                          26                 Type 2 diabetes
  Drucker^31^         2008   303            Exenatide once weekly; exenatide twice daily         30                 Type 2 diabetes
  Garber^32^          2009   746            Liraglutide; glimepiride                             52                 Type 2 diabetes
  Heine^33^           2005   551            Exenatide; insulin glargine                          26                 Type 2 diabetes
  Kendall^34^         2005   733            Exenatide; placebo                                   30                 Type 2 diabetes
  Marre^35^           2009   1041           Liraglutide; rosiglitazone; placebo                  26                 Type 2 diabetes
  Moretto^36^         2008   232            Exenatide; placebo                                   24                 Type 2 diabetes
  Nauck^37^           2007   501            Exenatide; insulin                                   53                 Type 2 diabetes
  Nauck^38^           2009   1091           Liraglutide; glimepiride; placebo                    26                 Type 2 diabetes
  Pratley^39^         2010   665            Liraglutide; sitagliptin                             26                 Type 2 diabetes
  Russell-Jones^40^   2009   581            Liraglutide; insulin glargine; placebo               26                 Type 2 diabetes
  Zinman^41^          2009   533            Liraglutide; placebo, metformin, and rosiglitazone   26                 Type 2 diabetes

The included trials assessed exenatide twice daily (n=13 trials),[@ref18] [@ref19] [@ref20] [@ref21] [@ref24] [@ref25] [@ref27] [@ref28] [@ref29] [@ref33] [@ref34] [@ref36] [@ref38] liraglutide (n=8),[@ref17] [@ref26] [@ref32] [@ref35] [@ref37] [@ref39] [@ref40] [@ref41] and exenatide once weekly (n=4; table 1).[@ref22] [@ref23] [@ref30] [@ref31] Three trials directly compared exenatide twice daily with liraglutide or with exenatide once weekly.[@ref23] [@ref26] [@ref31]. The dose of liraglutide given in most trials was 1.2 or 1.8 mg/day; one trial of obese individuals without diabetes also used doses of 2.4 and 3 mg/day.[@ref17] The doses of exenatide used were 10 to 20 µg/day or 2 mg/week. The GLP-1R agonists were given as subcutaneous injections once daily for liraglutide, and twice daily and once weekly for exenatide. The control groups received placebo, third generation sulphonylurea compounds, insulin, dipeptidyl peptidase 4 inhibitors, thiazolidinediones, or metformin. In trials of patients with type 2 diabetes, cointerventions given to the intervention and control group included metformin, sulphonylurea compounds, or thiazolidinediones.

Quality of bias control
-----------------------

Allocation sequence generation and allocation concealment were adequate in all trials. None of the trials found differences in the baseline characteristics of participants between the GLP-1R agonist and control groups. Thirteen trials were double blind, with masking of both patients and investigators. None of the included trials reported the success of blinding. All trials reported clinically relevant outcome measures, provided a clear description of losses to follow-up, accounted for patients with missing data in the analyses, and undertook sample size calculations. None of the trials were terminated prematurely. We found no evidence of reporting bias when comparing published trial protocols with subsequent trial reports.

Body weight
-----------

All trials reported weight loss. We did a random effects meta-analysis including 3395 participants randomly assigned to GLP-1R agonists and 3016 assigned to the control groups, from 21 trials (fig 2[](#fig2){ref-type="fig"}). The control groups in the analysis received placebo, oral antidiabetic drugs, or insulin (table 1). The mean reduction in body weight achieved with the highest dose of GLP-1R agonists ranged from --7.2 to --0.2 kg. The weighted mean change in body weight was larger for patients in the GLP-1R agonist group than for those in the control group (--2.9 kg, 95% confidence interval --3.6 to --2.2). We found evidence of intertrial heterogeneity in the analysis (tau^2^=2.4, P\<0.01). Subgroup analyses showed a greater weight loss after treatment with the highest doses of GLP-1R agonists. We saw a weight reduction in patients without diabetes (--3.2 kg, --4.3 to --2.1) as well as in those with diabetes (--2.8 kg, --3.4 to --2.3).

![**Fig 2** Meta-analysis of change in body weight (kg) in included trials after at least 20 weeks of treatment, using random effects model](vilt892349.f2_default){#fig2}

A repeat of the initial meta-analyses with fixed effects models confirmed the primary meta-analysis. The regression analysis did not show any clear evidence of bias or small study effects (Egger's test, P\>0.1 for all analyses). We saw no difference in bodyweight changes for patients assigned liraglutide versus exenatide twice daily (−0.4 kg, 95% confidence interval --1.3 to 0.6), or for those assigned exenatide as a long acting release versus exenatide twice daily (--0.6 kg, --1.5 to 0.3). Subgroup analyses showed a weight reduction in trials assessing exenatide twice daily (--2.8 kg, --2.9 to --2.7), exenatide once weekly (--2.8 kg, --5.2 to --0.3), and liraglutide (--2.2 kg, --3.5 to --0.9). We also saw a weight reduction for trials in which the control group received placebo (--1.9 kg, --2.9 to --0.9; 10 trials), insulin (--4.8 kg, --5.1 to --4.5; six trials), oral antidiabetic drugs including metformin or sulphonylurea compounds (--3.0 kg, --4.9 to --1.2; three trials), and dipeptidyl peptidase 4 inhibitors (--2.0 kg, --2.9 to --1.1; two trials). Random effects meta-regression of the primary meta-analysis found that body mass index at baseline and trial duration did not predict the size of the estimated intervention or explain intertrial heterogeneity (P=0.293 and P=0.284, respectively).

We did the sequential analysis based on the results of the primary meta-analysis, including the highest dose of GLP-1R agonists assessed compared with controls. The analysis showed that the cumulative *Z* curve crossed the monitoring boundary after the seventh trial, which suggested that we had sufficient evidence (that is, the optimal information size was reached) to confirm the intervention effect after adjusting for multiple testing and random error.

Blood pressure, cholesterol, and liver enzymes
----------------------------------------------

Random effects meta-analyses found that the GLP-1R agonists reduced systolic blood pressure (fig 3[](#fig3){ref-type="fig"}), diastolic blood pressure (fig 4[](#fig4){ref-type="fig"}), and total cholesterol concentrations (fig 5[](#fig5){ref-type="fig"}). We found no evidence of bias for the analysis of systolic or diastolic blood pressure (Egger's test, P=0.500 and P=0.107, respectively) or cholesterol (P=0.081).

![**Fig 3** Meta-analysis of change in systolic blood pressure (mm Hg) in included trials after at least 20 weeks of treatment, using random effects model](vilt892349.f3_default){#fig3}

![**Fig 4** Meta-analysis of change in diastolic blood pressure (mm Hg) in included trials after at least 20 weeks of treatment, using random effects model](vilt892349.f4_default){#fig4}

![**Fig 5** Meta-analysis of change in concentration of total cholesterol (mmol/L) in included trials after at least 20 weeks of treatment, using random effects model](vilt892349.f5_default){#fig5}

We retrieved data for liver enzymes from 17 trials. However, since these data were reported inconsistently, we were only able to include data from 12 of these trials (fig 6[](#fig6){ref-type="fig"}). The overall difference in concentrations of alanine aminotransferase was significant in the fixed effects meta-analysis, but not in the random effects analysis (--1.0 U/L, 95% confidence interval --2.5 to 0.6). In subgroup analyses, alanine aminotransferase concentrations decreased after treatment with liraglutide (--2.2 U/L, --3.6 to --0.9) but not with exenatide (0.7 U/L, --1.1 to 2.4). GLP-1R agonists did not have a clear effect on alkaline phosphatase concentrations after treatment in the overall analysis (1.1 U/L, --0.6 to 2.8) or in separate analyses of liraglutide or exenatide. We also did not see any evidence of small study effects in regression analyses (Egger's test; alanine aminotransferase, P=0.371; alkaline phosphatase, P=0.123).

![**Fig 6** Meta-analysis of change in concentration of alanine aminotransferase (U/L) in included trials after at least 20 weeks of treatment, using fixed effects model](vilt892349.f6_default){#fig6}

Glycaemic control (patients with type 2 diabetes)
-------------------------------------------------

In patients with type 2 diabetes, the highest doses of GLP-1R agonists reduced HbA~1c~ percentage compared with placebo, oral antidiabetic drugs, or insulin (fig 7[](#fig7){ref-type="fig"}; Egger's test, P=0.764). In the random effects analysis, we saw no clear difference in the change in mean concentration of fasting blood glucose between the highest doses of GLP-1R agonists and controls (--0.51 mmol/L, 95% confidence interval --1.09 to 0.07; tau^2^=1.06; χ^2^ test, P\<0.01; Egger's test, P=0.487). When using a fixed effects model, we found that GLP-1R agonists were associated with a greater reduction in concentrations of fasting glucose than controls (--1.32 mmol/L, --1.35 to --1.29).

The proportion of participants who achieved the haemoglobin target (HbA~1c~ \<7%) was higher in the GLP-1R agonists group than in controls (relative risk 1.98, 95% confidence interval 1.46 to 2.70; tau^2^=0.28; χ^2^ test, P=0.10). The corresponding number needed to treat was six patients (four to 10 patients). Egger's test found evidence of small study effects (P=0.001). Repeating the primary analysis with a fixed effects model confirmed the overall results (relative risk 1.75, 1.59 to 1.92). We found similar results for trials using a lower dose of GLP-1R agonist (that is, liraglutide 1.2 mg/day and exenatide 10 µg/day).

When comparing the highest dose with the lowest dose of GLP-1R agonists assessed in the individual trials, random effects meta-analysis showed that the highest doses were associated with a greater reduction in mean HbA~1c~ (--0.10%, --0.17% to --0.02%) and increased the proportion of patients who achieved the target HbA~1c~ (relative risk 1.14, 1.03 to 1.27). We saw no difference between the two highest and lowest doses when analysing the mean reduction in fasting blood glucose (weighted mean difference --0.14 mmol/L, --0.31 to 0.03). We saw a similar result after repeating the meta-analyses with fixed effects models.

![**Fig 7** Meta-analysis of reduction in HbA~1c~ percentage in included trials after at least 20 weeks of treatment, using random effects model](vilt892349.f7_default){#fig7}

Adverse events
--------------

The trials registered several adverse events (table 2[](#tbl2){ref-type="table"}). Overall, GLP-1R agonists did not increase the number of patients who withdrew or dropped out. The most frequent adverse events were hypoglycaemia and gastrointestinal adverse events (nausea, diarrhoea, and vomiting). Adverse events became more frequent with increasing doses. We found few serious adverse events (such as major episodes of hypoglycaemia).

###### 

 Adverse events in randomised controlled trials, by specific comparisons

  Adverse event                                                  Comparator group (n/N)   Relative risk (95% CI)   
  -------------------------------------------------------------- ------------------------ ------------------------ ---------------------
  **High dose GLP-1R agonists *v* control interventions\*†**                                                       
  Withdrawal                                                     578/3142                 616/2768                 0.85 (0.71 to 1.0)
  Hypoglycaemia (major episodes)                                 341 (10)/2281            342 (16)/2036            0.98 (0.60 to 1.59)
  Nausea                                                         935/2845                 219/2556                 4.33 (3.16 to 5.94)
  Vomiting                                                       277/2494                 100/2245                 2.91 (1.93 to 4.39)
  Diarrhoea                                                      305/2411                 127/2157                 2.19 (1.79 to 2.68)
  **High dose GLP-1R agonists *v* low dose GLP-1R agonists†‡**                                                     
  Withdrawal                                                     346/1893                 423/1658                 0.71(0.60 to 0.85)
  Hypoglycaemia (major episodes)                                 168 (0)/1335             119 (0)/1214             1.57 (0.65 to 3.81)
  Nausea                                                         469/1425                 134/1312                 3.96 (2.67 to 5.87)
  Vomiting                                                       150/1425                 69/1312                  2.67 (1.47 to 4.84)
  Diarrhoea                                                      171/1247                 65/1135                  2.35 (1.78 to 3.10)
  **Low dose GLP-1R agonists *v* control interventions\*‡**                                                        
  Withdrawal                                                     332/1665                 392/1426                 0.71 (0.52 to 0.97)
  Hypoglycaemia (major episodes)                                 134 (1)/1342             119 (0)/1214             1.37 (0.75 to 2.52)
  Nausea                                                         399/1665                 136/1426                 3.21 (2.18 to 4.72)
  Vomiting                                                       131/1437                 69/1312                  2.32 (1.03 to 5.21)
  Diarrhoea                                                      121/1259                 65/1135                  1.70 (1.27 to 2.28)

\*Control interventions: placebo, oral antidiabetic medication, or insulin.

†High doses: 20 µg/day for exenatide; 1.8 mg/day for liraglutide.

‡Low doses: 10 µg/day for exenatide; 1.2 mg/day for liraglutide.

Discussion
==========

The present meta-analyses include data from randomised controlled trials assessing clinically relevant doses of GLP-1R agonists given for at least 20 weeks. The results indicate that treatment with GLP-1R agonists help reduce body weight in patients who are overweight or obese. Three of the included trials assessed the effect of GLP-1R agonists on patients without type 2 diabetes and 22 assessed patients with type 2 diabetes. GLP-1R agonists also had beneficial effects on systolic and diastolic blood pressure. In subgroup and sensitivity analyses, the liver enzyme activity was lower in the GLP-1R agonist groups than in the control groups. However, the overall effect of GLP-1R agonists on liver enzymes was not clear. For patients with type 2 diabetes, GLP-1R agonists improved glycaemic control (as assessed by HbA~1c~ percentage and fasting plasma glucose) and increased the proportion of patients who achieved the target haemoglobin.

GLP-1R agonists were associated with several adverse events. Gastrointestinal side effects (such as nausea, vomiting, and diarrhoea) were common, but did not seem to affect the number of losses to follow-up. These findings concur with recent evidence showing that the overall patient satisfaction with GLP-1R agonist treatment is relatively high.[@ref42]

In patients with type 2 diabetes, improved glycaemic control is often associated with increased body weight.[@ref43] We found that participants without diabetes achieved greater reductions in body weight than those with diabetes. Our results suggest that treatment with GLP-1R agonists are an effective intervention for participants who are overweight, irrespective of whether they have diabetes. GLP-1R agonists could be especially relevant for patients with hypertension, raised cholesterol, or other conditions in the metabolic syndrome. However, additional trials investigating the effect of comorbidities (such as cardiovascular diseases) are still warranted.

In developed countries, obesity increases mortality and morbidity as well as the frequency of type 2 diabetes, hypertension, and non-alcoholic fatty liver disease. Obesity, particularly with an excess of visceral or ectopic fat, is an independent risk factor for heart disease and several studies suggest that obesity has detrimental effects on complications to infectious diseases,[@ref44] quality of life and depression,[@ref45] and cancer related mortality.[@ref46] These diseases have an important impact on the individuals affected, and the management of complications to obesity puts an increasing strain on the healthcare systems. A recent German study found that the cost associated with obesity is apparent even from childhood.[@ref47] Since nearly 50 million children under the age of 5 years are overweight,[@ref2] we are facing a huge medical, as well as financial, challenge worldwide. Accordingly, identification of effective interventions for weight reductions is crucial. The costs with interventions that lead to lasting weight reduction should be considered in relation to those with the treatment of complications to obesity.

In 2005, the US Food and Drug Administration approved the first long acting stable GLP-1R agonist. Two products are currently available on the market: exenatide (Byetta; Eli Lilly) and liraglutide (Victoza; Novo Nordisk). Both drugs are injectable medications that can be used in combination with oral antidiabetic drugs such as metformin, thiazolidinediones, or sulphonylurea compounds. The treatments are approved for patients with type 2 diabetes who have not achieved adequate glycaemic control after treatment with conventional antidiabetic interventions. Exenatide treatment is initiated at a 5 µg dose given twice daily for at least one month to improve tolerability. The dose can subsequently be increased to a maximum of 10 µg twice daily to improve glycaemic control.[@ref48]

In October 2011, exenatide as a once weekly injection (Bydureon; Eli Lilly) reached the European market for the treatment of type 2 diabetes, with similar indications as for exenatide twice daily and liraglutide. The starting dose of exenatide once weekly is 2 mg/week with no need for titration. The starting dose of liraglutide is 0.6 mg/day; after one week, the daily dose is increased to 1.2 mg, based on the clinical response and side effects, and can be increased further to 1.8 mg/day the following week, depending on efficacy and adverse events.[@ref49] The trials included in the present review followed these intervention regimens, although one trial also assessed liraglutide doses of 2.4-3.0 mg/day in obese individuals without diabetes.[@ref17] These doses seemed to further increase not only the achieved bodyweight loss, but also the number of gastrointestinal adverse events.[@ref17] None of the remaining trials assessed equally high doses.

Patients with obesity and type 2 diabetes have an increased risk of developing non-alcoholic fatty liver disease.[@ref50] This disease could have a benign course, although it progresses to non-alcoholic steatohepatitis in about 20-30% of patients. Although histological markers remain the best method for assessing the severity of fatty liver disease, liver enzymes are associated with the disease activity in the early stages of non-alcoholic steatohepatitis. We found no clear effect of GLP-1R agonists on liver enzyme activity. However, since we did not analyse histological changes, additional trials are needed to investigate the effects of GLP-1R agonists in participants with overweight and non-alcoholic fatty liver disease.

Strengths and limitations of the findings
-----------------------------------------

Unlike previous reviews, we were able to gather data for outcomes that were not described in the published reports.[@ref17] [@ref19] [@ref22] [@ref24] [@ref25] [@ref26] [@ref30] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35] [@ref36] [@ref37] [@ref39] [@ref40] Outcome measures are less likely to be described in published reports if the result is not significant. Therefore, the retrieval of unpublished outcome data could reduce the risk of reporting bias (that is, selective reporting of outcomes with a positive result). The present review also differed from previous reviews by the inclusion of patients without type 2 diabetes mellitus. Although the non-specific inclusion criteria increased intertrial heterogeneity, they also improved the external validity of our findings. Furthermore, to achieve and maintain clinically relevant weight loss, we only included trials that followed participants for a sufficient period (20 weeks or more).

Inadequate randomisation and attrition bias could lead to overestimated benefits of an intervention. None of the included trials had deficiencies in the reported randomisation methods and all accounted for the intention to treat population in their results and analyses. These aspects support the internal validity of our findings. Since we only included trials that used clinically relevant doses given for clinically relevant treatment periods, the results can be extrapolated to clinical practice. Accordingly, the present review can help evidence based practitioners determine the size of the treatment benefit.

All the included trials received industry funding. Previous evidence and clinical examples have described that financial interests could lead to bias in intervention comparisons.[@ref16] On the other hand, funding could be associated with adequate control of bias.[@ref51] Furthermore, in a large cohort of randomised trials, industry funding was associated with more positive author conclusions, but not with the quantitative results of the trials.[@ref52] Since we did not identify trials without funding, we were unable to make subgroup analyses to explore the potential effect of competing interests. We did, however, undertake rigorous assessments of the quality of included trials. None of our analyses showed any evidence of selection, assessment, attrition, or outcome reporting bias. These analyses support the validity of our results.

Conclusions and clinical implications
-------------------------------------

Participants who are overweight are likely to develop type 2 diabetes, hypertension, hypercholesterolaemia, liver disease, and eventually cardiovascular disease. Accordingly, these participants have a considerably elevated risk of morbidity and mortality. Traditional treatments for obesity are, unfortunately, often short lived and consequently not especially effective.

Current treatments for patients with type 2 diabetes are associated with shortcomings (weight gain, hypoglycaemia, and other side effects) that limit the number of patients reaching acceptable therapeutic goals. The present meta-analysis provides convincing evidence that GLP-1R agonists, when given to obese patients with or without diabetes, results in clinically relevant beneficial effects on body weight. Additional beneficial effects on blood pressure and total cholesterol might also be achieved. The intervention should be considered in patients with diabetes who are obese or overweight. Further studies are needed to elucidate the effects of GLP-1R agonists in the treatment of obese patients without diabetes.

### What is already known on this topic

1.  Improved glycaemic control is associated with increased body weight

2.  Agonists to the glucagon-like peptide-1 receptor (GLP-1R) enhance glucose homoeostasis and suppress food intake and appetite

### What this study adds

1.  Treatment with clinically relevant doses of GLP-1R agonists for at least 20 weeks leads to weight loss in obese or overweight patients with or without type 2 diabetes mellitus in spite of an improved metabolic regulation

2.  The effect of GLP-1R agonists could be more pronounced in patients without diabetes

3.  GLP-1R agonists also reduce systolic and diastolic blood pressure and total cholesterol
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